Stefano Indraccolo

List of Publications by Year
in descending order

186 papers	7,386 citations	61687 45 h-index	78623 77 g-index
189 all docs	189 docs citations	189 times ranked	13909 citing authors

#	Article	IF	Citations
1	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115.	1.9	25
2	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. British Journal of Cancer, 2022, 127, 383-393.	2.9	36
3	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. Redox Biology, 2022, 51, 102268.	3.9	14
4	SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. Leukemia, 2021, 35, 377-388.	3.3	68
5	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro-Oncology, 2021, 23, 264-276.	0.6	48
6	Filling the gap between risk assessment and molecular determinants of tumor onset. Carcinogenesis, 2021, 42, 507-516.	1.3	3
7	Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics, 2021, 11, 1594-1608.	4.6	3
8	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Translational Lung Cancer Research, 2021, 10, 202-220.	1.3	29
9	Genetic Perturbation of Pyruvate Dehydrogenase Kinase 1 Modulates Growth, Angiogenesis and Metabolic Pathways in Ovarian Cancer Xenografts. Cells, 2021, 10, 325.	1.8	9
10	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. Frontiers in Oncology, 2021, 11, 625636.	1.3	8
11	Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma. Biology, 2021, 10, 363.	1.3	7
12	A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. Blood, 2021, 138, 1317-1330.	0.6	11
13	Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures. Nature Communications, 2021, 12, 2507.	5.8	22
14	BBIT20 inhibits homologous DNA repair with disruption of the BRCA1â€“BARD1 interaction in breast and ovarian cancer. British Journal of Pharmacology, 2021, 178, 3627-3647.	2.7	13
15	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. Critical Reviews in Oncology/Hematology, 2021, 163, 103378.	2.0	12
16	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527.	1.1	7
17	Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics, 2021, 11, 1468.	1.3	7
18	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonâ€“small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	1.1	19

#	Article	IF	Citations
19	Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 66.	1.8	12
20	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics, 2020, 10, 765.	1.3	7
21	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open, 2020, 5, e000748.	2.0	2
22	In situ Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology Approach. Frontiers in Oncology, 2020, 10, 1277.	1.3	8
23	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. Cancers, 2020, 12, 2283.	1.7	41
24	Genetic perturbation of IFN-Î± transcriptional modulators in human endothelial cells uncovers pivotal regulators of angiogenesis. Computational and Structural Biotechnology Journal, 2020, 18, 3977-3986.	1.9	6
25	Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. British Journal of Cancer, 2020, 123, 81-91.	2.9	35
26	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Clinical Cancer Research, 2020, 26, 4478-4484.	3.2	20
27	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. Oncologist, 2020, 25, e1996-e2005.	1.9	21
28	Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment. International Journal of Molecular Sciences, 2020, 21, 1601.	1.8	7
29	Metabolism in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1263, 1-11.	0.8	11
30	Comparison of the Genomic Profile of Cancer Stem Cells and Their Non-Stem Counterpart: The Case of Ovarian Cancer. Journal of Clinical Medicine, 2020, 9, 368.	1.0	10
31	Evolving use of liquid biopsy in non-small-cell-lung cancer patients. International Journal of Biological Markers, 2020, 35, 23-25.	0.7	3
32	Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts. Haematologica, 2020, 105, 1317-1328.	1.7	9
33	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 607840.	1.3	10
34	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. Cancer Treatment Reviews, 2020, 87, 102031.	3.4	82
35	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	1.7	6
36	Editorial on â€œThe AvaALL Randomized Clinical Trialâ€• Journal of Thoracic Disease, 2019, 11, S1237-S1240.	0.6	1

#	Article	IF	Citations
37	Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983954.	1.4	35
38	Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer. BMC Cancer, 2019, 19, 821.	1.1	22
39	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Nonâ€“Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	3.2	139
40	PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. Critical Reviews in Oncology/Hematology, 2019, 135, 128-134.	2.0	66
41	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 1874.	1.8	39
42	LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-16.	1.9	78
43	18F-FDG PET/CT in non-small-cell lung cancer patients. Nuclear Medicine Communications, 2019, 40, 802-807.	0.5	63
44	Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. Cells, 2019, 8, 1601.	1.8	25
45	Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Journal of Hepatology, 2019, 70, 700-709.	1.8	112
46	Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. Clinical Cancer Research, 2019, 25, 1828-1837.	3.2	72
47	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 110-119.	5.1	238
48	Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study.. Journal of Clinical Oncology, 2019, 37, 2043-2043.	0.8	2
49	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist, 2019, 24, e318-e326.	1.9	5
50	Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases. Translational Lung Cancer Research, 2019, 8, S435-S438.	1.3	2
51	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.. Journal of Clinical Oncology, 2019, 37, e20612-e20612.	0.8	0
52	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876374.	1.4	30
53	Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. Oncogene, 2018, 37, 3839-3851.	2.6	26
54	LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and I3-irradiation. Biochemical Pharmacology, 2018, 156, 479-490.	2.0	30

#	Article	IF	Citations
55	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. Journal of Thoracic Oncology, 2018, 13, 1692-1704.	0.5	74
56	Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40.	1.5	61
57	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1021-1030.	1.1	21
58	Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis. Cell Death and Disease, 2018, 9, 822.	2.7	23
59	Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth. Frontiers in Oncology, 2018, 8, 195.	1.3	10
60	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology, 2018, 36, 2047-2047.	0.8	4
61	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.. Journal of Clinical Oncology, 2018, 36, e24074-e24074.	0.8	0
62	Abstract 2406: Metabolic phenotype and metastasis in patient-derived ovarian cancer xenografts. , 2018, , .		0
63	The Nucleotide Kinase Nadk Is Required for ROS Detoxification and Constitutes a Metabolic Vulnerability of NOTCH1-Driven T-ALL. Blood, 2018, 132, 2615-2615.	0.6	1
64	Linking metabolic reprogramming to therapy resistance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 1-6.	3.3	117
65	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Nonâ€“Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. Clinical Cancer Research, 2017, 23, 3316-3324.	3.2	43
66	Absence of Neurofibromin Induces an Oncogenic Metabolic Switch via Mitochondrial ERK-Mediated Phosphorylation of the Chaperone TRAP1. Cell Reports, 2017, 18, 659-672.	2.9	81
67	Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. Scientific Reports, 2017, 7, 13936.	1.6	45
68	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. Critical Reviews in Oncology/Hematology, 2017, 119, 30-39.	2.0	40
69	Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors. British Journal of Pharmacology, 2017, 174, 3094-3106.	2.7	46
70	Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood, 2017, 130, 2750-2761.	0.6	54
71	Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells. Oncotarget, 2017, 8, 6433-6445.	0.8	29
72	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology, 2017, 35, TPS2085-TPS2085.	0.8	3

#	Article	IF	Citations
73	ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. Oncotarget, 2017, 8, 26129-26141.	0.8	21
74	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget, 2017, 8, 32626-32638.	0.8	14
75	Modulation of the anti-tumor activity of VEGF blockade by metformin.. Journal of Clinical Oncology, 2017, 35, e23009-e23009.	0.8	0
76	Next generation sequencing in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD). , 2017, , .		0
77	Potential of Induced Metabolic Bioluminescence Imaging to Uncover Metabolic Effects of Antiangiogenic Therapy in Tumors. Frontiers in Oncology, 2016, 6, 15.	1.3	5
78	In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. Frontiers in Oncology, 2016, 6, 164.	1.3	8
79	An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death and Disease, 2016, 7, e2047-e2047.	2.7	15
80	166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series. Journal of Thoracic Oncology, 2016, 11, S130.	0.5	0
81	28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS). Journal of Thoracic Oncology, 2016, 11, S67.	0.5	0
82	77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC). Journal of Thoracic Oncology, 2016, 11, S88.	0.5	1
83	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Reports, 2016, 15, 1134-1143.	2.9	96
84	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. Journal of Leukocyte Biology, 2016, 99, 1077-1087.	1.5	41
85	Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research, 2016, 76, 4775-4784.	0.4	44
86	Reconstruction of gene regulatory modules from RNA silencing of IFN-Î± modulators: experimental set-up and inference method. BMC Genomics, 2016, 17, 228.	1.2	3
87	Vascular endothelial growth factor blockade elicits a stable metabolic shift in tumor cells: therapeutic implications. Molecular and Cellular Oncology, 2016, 3, e1008307.	0.3	2
88	Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation. Leukemia, 2016, 30, 812-822.	3.3	15
89	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. Lung Cancer, 2016, 96, 52-55.	0.9	8
90	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	0.8	15

#	Article	IF	Citations
91	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. Oncotarget, 2016, 7, 33081-33095.	0.8	15
92	Uncovering Metabolic Effects of Anti-angiogenic Therapy in Tumors by Induced Metabolic Bioluminescence Imaging. Methods in Molecular Biology, 2016, 1464, 175-184.	0.4	2
93	Pharmacological Inhibition of Lck is Able to Revert Glucocorticoid Resistance in Pediatric T-ALL. Blood, 2016, 128, 838-838.	0.6	0
94	EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. BMC Cancer, 2015, 15, 855.	1.1	13
95	Metformin: a modulator of bevacizumab activity in cancer? A case report. Cancer Biology and Therapy, 2015, 16, 210-214.	1.5	13
96	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death and Disease, 2015, 6, e1774-e1774.	2.7	28
97	Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. Cellular Oncology (Dordrecht), 2015, 38, 377-385.	2.1	11
98	VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells. Cancer Research, 2015, 75, 120-133.	0.4	62
99	DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice. Carcinogenesis, 2015, 36, 115-121.	1.3	33
100	Abstract 1182: Metformin affects breast cancer cell growth and disturbs an IGF1/insulin related gene network that correlates with breast cancer progression. Cancer Research, 2015, 75, 1182-1182.	0.4	0
101	Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget, 2014, 5, 4305-4319.	0.8	249
102	Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia, 2014, 28, 278-288.	3.3	108
103	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. British Journal of Cancer, 2014, 111, 25-32.	2.9	41
104	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 4647-4659.	3.2	130
105	Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 2324-2335.	3.3	147
106	NOTCH3 Signaling Regulates MUSASHI-1 Expression in Metastatic Colorectal Cancer Cells. Cancer Research, 2014, 74, 2106-2118.	0.4	56
107	Metabolic effects of antiangiogenic drugs in tumors: Therapeutic implications. Biochemical Pharmacology, 2014, 89, 162-170.	2.0	20
108	Wnt activation promotes neuronal differentiation of Glioblastoma. Cell Death and Disease, 2013, 4, e500-e500.	2.7	89

#	Article	IF	Citations
109	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	7.7	220
110	hTERT Inhibition Triggers Epsteinâ€“Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. Clinical Cancer Research, 2013, 19, 2036-2047.	3.2	27
111	Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology, 2013, 58, 1042-1053.	3.6	139
112	Insights into the Regulation of Tumor Dormancy by Angiogenesis in Experimental Tumors. Advances in Experimental Medicine and Biology, 2013, 734, 37-52.	0.8	18
113	ZNF521 Is a Zinc Finger Protein That Prevents Differentiation Of Human MLL-AF9-Positive Myeloid Leukemic Cells. Blood, 2013, 122, 1255-1255.	0.6	0
114	BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1Î± stability and MGMT expression. Cell Death and Disease, 2012, 3, e412-e412.	2.7	132
115	Signaling Pathways in Cancer Stem Cells: Therapeutic Implications. , 2012, , 3-11.		0
116	Metabolic effects of anti-angiogenic therapy in tumors. Biochimie, 2012, 94, 925-931.	1.3	12
117	Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS Journal, 2012, 279, 882-891.	2.2	33
118	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood, 2011, 117, 7053-7062.	0.6	199
119	Efficacy Assessment of Interferon-Alphaâ€“Engineered Mesenchymal Stromal Cells in a Mouse Plasmacytoma Model. Stem Cells and Development, 2011, 20, 709-719.	1.1	19
120	Notch3 signalling promotes tumour growth in colorectal cancer. Journal of Pathology, 2011, 224, 448-460.	2.1	77
121	Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology, 2011, 54, 890-899.	3.6	82
122	Vandetanib Improves Anti-Tumor Effects of L19mTNFÎ± in Xenograft Models of Esophageal Cancer. Clinical Cancer Research, 2011, 17, 447-458.	3.2	20
123	Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormoneâ€“Regulated Tumors. Molecular Cancer Therapeutics, 2011, 10, 1600-1610.	1.9	53
124	Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization. Cancer Research, 2011, 71, 4214-4225.	0.4	67
125	Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clinical and Experimental Metastasis, 2010, 27, 419-439.	1.7	15
126	Ligand-driven activation of the Notch pathway in T-all and solid tumors: Why Not(ch)?. Cell Cycle, 2010, 9, 80-85.	1.3	16

#	Article	IF	Citations
127	Side population and cancer stem cells: Therapeutic implications. Cancer Letters, 2010, 288, 1-9.	3.2	109
128	Interferon-Î± as angiogenesis inhibitor: Learning from tumor models. Autoimmunity, 2010, 43, 244-247.	1.2	75
129	M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis. Clinical Cancer Research, 2010, 16, 5233-5243.	3.2	124
130	Cross-talk between Tumor and Endothelial Cells Involving the Notch3-Dll4 Interaction Marks Escape from Tumor Dormancy. Cancer Research, 2009, 69, 1314-1323.	0.4	124
131	The Angiogenic Switch: Implications in the Regulation of Tumor Dormancy. Current Molecular Medicine, 2009, 9, 935-941.	0.6	58
132	Interferon-Î± counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis, 2009, 30, 851-860.	1.3	33
133	Impact of VEGFâ€dependent tumour microâ€environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. Journal of Pathology, 2009, 219, 455-462.	2.1	17
134	Hypoxia and HIF1Î± Repress the Differentiative Effects of BMPs in High-Grade Glioma. Stem Cells, 2009, 27, 7-17.	1.4	100
135	Antineoplastic activity of lentiviral vectors expressing interferon-Î± in a preclinical model of primary effusion lymphoma. Blood, 2009, 113, 4525-4533.	0.6	18
136	Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. Apmis, 2008, 116, 648-659.	0.9	52
137	Tumor-Targeted Interferon-Î± Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. Cancer Cell, 2008, 14, 299-311.	7.7	267
138	Hypoxia Inducible Factor-1Î± Inactivation Unveils a Link between Tumor Cell Metabolism and Hypoxia-Induced Cell Death. American Journal of Pathology, 2008, 173, 1186-1201.	1.9	39
139	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-Î± Antitumor Effects. Cancer Research, 2008, 68, 5658-5668.	0.4	121
140	Identification of Genes Selectively Regulated by IFNs in Endothelial Cells. Journal of Immunology, 2007, 178, 1122-1135.	0.4	152
141	Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. Cancer Research, 2007, 67, 8605-8614.	0.4	41
142	Concluding remarks. Molecular Aspects of Medicine, 2007, 28, 167.	2.7	1
143	RNA interference: Implications for cancer treatment. Molecular Aspects of Medicine, 2007, 28, 143-166.	2.7	60
144	Anti-angiogenic gene therapy of cancer: Current status and future prospects. Molecular Aspects of Medicine, 2007, 28, 87-114.	2.7	62

#	Article	IF	Citations
145	Angiogenesis meets immunology: Cytokine gene therapy of cancer. Molecular Aspects of Medicine, 2007, 28, 59-86.	2.7	18
146	Genes in the cure of cancer. Molecular Aspects of Medicine, 2007, 28, 1-3.	2.7	1
147	hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis. International Journal of Cancer, 2007, 121, 576-587.	2.3	33
148	Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 â^'/â^' epithelial ovarian cancers. European Journal of Cancer, 2006, 42, 1475-1483.	1.3	28
149	Gene therapy of ovarian cancer with IFN-Î±-producing fibroblasts: comparison of constitutive and inducible vectors. Gene Therapy, 2006, 13, 953-965.	2.3	19
150	Dormant Tumors Awaken by a Short-Term Angiogenic Burst: The Spike Hypothesis. Cell Cycle, 2006, 5, 1751-1755.	1.3	46
151	Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4216-4221.	3.3	113
152	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	0.6	38
153	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. British Journal of Haematology, 2005, 130, 878-889.	1.2	11
154	Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: Microarray gene expression analyses. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 591, 198-211.	0.4	25
155	Interferon-Î± Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, 16, 957-970.	1.4	34
156	Interferon- Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, .	1.4	0
157	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. Journal of Immunological Methods, 2004, 291, 153-163.	0.6	6
158	Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epsteinâ€“Barr virus-immortalized B cells. Experimental Cell Research, 2004, 295, 539-548.	1.2	23
159	Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood, 2004, 104, 92-99.	0.6	181
160	Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field. Current Gene Therapy, 2004, 4, 297-308.	0.9	23
161	Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Experimental Cell Research, 2003, 287, 28-38.	1.2	24
162	Antiangiogenic Therapy Against Experimental Glioblastoma Using Genetically Engineered Cells Producing Interferon-Î±, Angiostatin, or Endostatin. Human Gene Therapy, 2003, 14, 883-895.	1.4	46

#	Article	IF	Citations
163	Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes. Human Gene Therapy, 2003, 14, 1155-1168.	1.4	171
164	Inhibition of Tumor Angiogenesis by Angiostatin: From Recombinant Protein to Gene Therapy. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 3-10.	1.7	37
165	Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. Gene, 2002, 283, 199-208.	1.0	11
166	Alternatively spliced forms of IgÎ± and IgÎ² prevent B cell receptor expression on the cell surface. European Journal of Immunology, 2002, 32, 1530.	1.6	19
167	Encapsulated cells producing retroviral vectors forin vivogene transfer. Journal of Gene Medicine, 2002, 4, 150-160.	1.4	21
168	The Isomerization Plant at Rosneft' Oil Companyâ€“Komsomol'sk Oil Refinery Open Joint-stock Company. Chemistry and Technology of Fuels and Oils, 2002, 38, 287-292.	0.2	0
169	Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Research, 2002, 62, 6099-107.	0.4	41
170	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood, 2001, 98, 3607-3617.	0.6	28
171	Modulation of Moloney Leukemia Virus Long Terminal Repeat Transcriptional Activity by the Murine CD4 Silencer in Retroviral Vectors. Virology, 2000, 276, 83-92.	1.1	10
172	Biochemical and genetic defects underlying human congenital hypotransferrinemia. The Hematology Journal, 2000, 1, 390-398.	2.0	28
173	Mutator Phenotype in Human Hematopoietic Neoplasms and Its Association With Deletions Disabling DNA Repair Genes and bcl-2 Rearrangements. Blood, 1999, 94, 2424-2432.	0.6	29
174	Frequency of a Mutated CCR-5 Allele (Delta32) among Italian Healthy Donors and Individuals at Risk of Parenteral HIV Infection. AIDS Research and Human Retroviruses, 1999, 15, 337-344.	0.5	20
175	DNA Immunization of Mice against SIVmac239 Gag and Env Using Rev-Independent Expression Plasmids. AIDS Research and Human Retroviruses, 1998, 14, 83-90.	0.5	22
176	TCR Expression and Clonality Analysis in Peripheral Blood and Lymph Nodes of HIV-Infected Patients. Human Immunology, 1997, 57, 93-103.	1.2	13
177	Identification of a human endogenous LTR-like sequence using HIV-1 LTR specific primers. Molecular and Cellular Probes, 1996, 10, 443-451.	0.9	3
178	Analysis of Epsteinâ€“Barr virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumours. Molecular and Cellular Probes, 1996, 10, 453-461.	0.9	7
179	The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Seminars in Immunology, 1996, 8, 249-254.	2.7	16
180	Genetic variability of the human CD4 V2 domain. Immunogenetics, 1996, 44, 70-72.	1.2	7

#	Article	IF	Citations
181	Genetic variability of the human CD4 V2 domain. Immunogenetics, 1996, 44, 70-72.	1.2	0
182	A CD3+CD8+ T Cell Population Lacking CD5 Antigen Expression Is Expanded in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients. Clinical Immunology and Immunopathology, 1995, 77, 253-261.	2.1	28
183	Dominance of a single Epstein-Barr virus strain in SCID-mouse tumors induced by injection of peripheral blood mononuclear cells from healthy human donors. Virus Research, 1995, 36, 215-231.	1.1	9
184	B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5? B cell subsets. Journal of Clinical Immunology, 1993, 13, 381-388.	2.0	25
185	Standardization of in vitro synthesis and detection of HIV-1-specific antibodies. Journal of Immunological Methods, 1993, 157, 105-115.	0.6	13
186	Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World. Frontiers in Oncology, 0, 12, .	1.3	1